Jci_page_head_homepage_01 Jci_page_head_homepage_02
Jean-Pierre Lévesque, Jean Hendy, Yasushi Takamatsu, Paul J. Simmons, Linda J. Bendall
Published in Volume 111, Issue 2
J Clin Invest. 2003; 111(2):187–196 doi:10.1172/JCI15994
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 7

Pretreatment of BM extracellular fluids from mobilized mice with a specific NE inhibitor together with a specific CG inhibitor prevents degradation and inactivation of CXCL12. Aliquots of synthetic human CXCL12α were incubated overnight at 37°C in the presence of BM extracellular fluids on day 4 of GCSF-induced mobilization and day 6 of CY-induced mobilization that were pretreated with 1 mM PMSF, 10 μM specific NE inhibitor MetOSuc-Ala-Ala-Pro-Val-CMK, or 10 μM specific CG inhibitor MetOSuc-Ala-Ala-Phe-PO(Phe)2 alone or in combination. In the top panel, the remaining chemotactic activity of exogenous human CXCL12α was measured on purified Nalm-6 cells in transmigration assays as described in Figure 4a. A representative experiment from two performed in triplicate is shown. The bottom panel shows Western blot analysis of the same samples with a goat anti-human CXCL12 antibody. G4, day 4 of GCSF-induced mobilization; CY6, day 6 of CY-induced mobilization.